<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373229">
  <stage>Registered</stage>
  <submitdate>1/07/2017</submitdate>
  <approvaldate>10/07/2017</approvaldate>
  <actrnumber>ACTRN12617000988358</actrnumber>
  <trial_identification>
    <studytitle>The physiological effects of high dose zopiclone in people with obstructive sleep apnoea 
</studytitle>
    <scientifictitle>The physiological effects of high dose zopiclone in people with obstructive sleep apnoea 


</scientifictitle>
    <utrn />
    <trialacronym>Zop2x</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnoea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>High dose zopiclone (15mg),  each participant to receive zopiclone once, immediately before bed. Zopiclone to be taken orally in front of the investigator for this acute in-laboratory study. 

1 week washout between visits. </interventions>
    <comparator>Placebo (sugar pill), taken orally in front of the investigator  (participants will act as their own controls in a cross-over design)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in sleep apnoea severity as measured by the apnoea hypopnoea index (AHI)</outcome>
      <timepoint>Acute overnight studies on zopiclone vs. placebo</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Genioglossus muscle activity during sleep (determined using fine wire electrodes)</outcome>
      <timepoint>Acute overnight studies on zopiclone vs. placebo</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory arousal threshold (negative pharyngeal pressure immediately prior to arousal from sleep, using an epiglottic pressure catheter inserted via the nostril) </outcome>
      <timepoint>Acute overnight studies on zopiclone vs. placebo</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Standard polysomnography variables (e.g. nadir SaO2, sleep efficiency, arousal index and sleep duration) </outcome>
      <timepoint>Acute overnight studies on zopiclone vs. placebo</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Otherwise healthy, men and women with obstructive sleep apnoea 

Patients who have a low respiratory arousal threshold  (between zero and -15cmH2O epiglottic pressure just prior to arousal) as estimated from their baseline sleep study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>64</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with confirmed overnight blood oxygen saturation nadir (SaO2) less than 70% from baseline sleep study
Patients with a high arousal threshold (less than -25cmH2O epiglottic pressure prior to arousal)

Patients taking medications known to affect sleep or muscle activity

Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study

Patients with any other medical condition which may interfere in the evaluation of the study
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>A sample size of n=30 will allow us to detect a 6 event/h sleep difference in the AHI with ~90% power (SD=9.8) with a two-tailed paired t-test (alpha=0.05)</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>10/07/2017</anticipatedstartdate>
    <actualstartdate>18/07/2017</actualstartdate>
    <anticipatedenddate>1/07/2019</anticipatedenddate>
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <currentsamplesize>3</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/07/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <postcode>2031 - Randwick</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Neuroscience Research Australia</primarysponsorname>
    <primarysponsoraddress>Margarete Ainsworth Building, 
Barker street,
Randwick 
NSW 2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC) CRE and Fellowship fundings</fundingname>
      <fundingaddress>National Health and Medical Research Council (NHMRC)
GPO Box 1421 
Canberra 
ACT, 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this physiology study is to determine the effects of high dose zopiclone  (15mg) on obstructive sleep apnoea severity, upper airway muscle activity, the respiratory arousal threshold and breathing parameters during sleep. </summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Sydney Local Health District HumanResearch Ethics Committee</ethicname>
      <ethicaddress>HREC
Room G71 East wing
Edmund Blacket Building 
Prince of Wales Hospital 
RAndwick
NSW 2031</ethicaddress>
      <ethicapprovaldate>20/06/2017</ethicapprovaldate>
      <hrec>16/355 (HREC/16/POWH/710)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick
NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia
Barker Street
Randwick
NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Danny Eckert </name>
      <address>Neuroscience Research Australia
Barker Street
Randwick
NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Danny Eckert </name>
      <address>Neuroscience Research Australia
Barker Street
Randwick
NSW 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>